PKKKRKV

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: PKKKRKV
• 英文别名: Nls (pkkkrkv)；(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-pyrrolidine-2-carbonyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-methylbutanoic acid
• 化学式: C₄₀H₇₈N₁₄O₈
• 分子量: 883.148
• InChiKey: HUQAPORYWLIQAO-YYGRSCHNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -5.1
• 重原子数：
  62
• 可旋转键数：
  34
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  392
• 氢给体数：
  14
• 氢受体数：
  14

反应信息

• 作为产物：
  描述：

  Fmoc-L-缬氨酸 、 Fmoc-L-脯氨酸 、 N-alpha-芴甲氧羰基-N-epsilon-叔丁氧羰基-L-赖氨酸 、 Fmoc-Pbf-L-精氨酸 生成 PKKKRKV
  参考文献：
  名称：

  钴ce肽生物共轭物显示增强的细胞摄取和定向核传递。

  摘要：

  DOI：

  10.1002/anie.200462519

文献信息

• Alpha, gamma-diaminobutyric acid (DAB) containing oligopeptide derivatives
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0834572A2

  公开（公告）日：1998-04-08

  alpha,gamma-Diaminobutyric acid (DAB) containing oligopeptide derivatives of formula         R'-NH-A     I wherein R'is a cell recognition agent, a membrane permeabilizing agent, a subcellular localization agent or a masking agent; Ais an oligopeptide devoid of one amino group and containing 1 to 200 amino acids, wherein at least one of the amino acid is alpha,gamma-diaminobutyric acids (DAB) and the terminal carboxyl group of the oligopeptide is converted into an amide, lower alkyl amide, di-lower alkyl amide or hydrazide are useful as a carrier for the transfection of cells with a polynucleotide or any other anionic macromolecule.

  含有式中α,γ-二氨基丁酸（DAB）的寡肽衍生物 R'-NH-A I 其中 R'是细胞识别剂、膜渗透剂、亚细胞定位剂或掩蔽剂； A是不含一个氨基且含有 1 至 200 个氨基酸的低聚肽，其中至少一个氨基酸是 α、γ-二氨基丁酸（DAB），低聚肽的末端羧基被转化为酰胺、低级烷基酰胺、二低级烷基酰胺或酰肼； -A 是不含一个氨基且含有 1 至 200 个氨基酸的低聚肽。 可用作多核苷酸或任何其他阴离子大分子转染细胞的载体。
• Prostate cancer gene
  申请人：GENSET

  公开号：EP1052292A1

  公开（公告）日：2000-11-15

  The present invention relates to PG1, a gene associated with prostate cancer. The invention provides polynucleotides including biallelic markers derived from PG1 and from flanking genomic regions. Primers hybridizing to these biallelic markers and regions flanking are also provided. This invention provides polynucleotides and methods suitable for genotyping a nucleic acid containing sample for one or more biallelic markers of the invention. Further, the invention provides methods to detect a statistical correlation between a biallelic marker allele and prostate cancer and between a haplotype and prostate cancer. The invention also relates to diagnostic methods of determining whether an individual is at risk for developing prostate cancer, and whether an individual suffers from prostate cancer as a result of a mutation in the PGl gene.

  本发明涉及与前列腺癌有关的基因 PG1。本发明提供的多核苷酸包括来自 PG1 和侧翼基因组区域的双拷贝标记。本发明还提供了与这些双拷贝标记和侧翼区域杂交的引物。本发明提供了适用于对含有本发明一个或多个双拷贝标记的核酸样本进行基因分型的多核苷酸和方法。此外，本发明还提供了检测双等位基因标记等位基因与前列腺癌之间以及单倍型与前列腺癌之间统计相关性的方法。本发明还涉及确定个体是否有罹患前列腺癌的风险以及个体是否因 PGl 基因突变而罹患前列腺癌的诊断方法。
• Self-assembling polynucleotide delivery system
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：EP1236473A2

  公开（公告）日：2002-09-04

  This invention provides a self-assembling polynucleotide delivery system comprising components aiding in the delivery of the polynucleotide to the desired address which are associated via noncovalent interactions with the polynucleotide. The components of this system include DNA-masking components, cell recognition components, charge-neutralization and membrane-permeabilization components, and subcellular localization components. Specific compounds useful in this system are also provided.

  本发明提供了一种自组装多核苷酸递送系统，该系统包含有助于将多核苷酸递送到所需地址的元件，这些元件通过与多核苷酸的非共价相互作用而相关联。该系统的成分包括 DNA 屏蔽成分、细胞识别成分、电荷中和成分、膜渗透成分和亚细胞定位成分。此外，还提供了对该系统有用的特定化合物。
• Methods and tools for identifying compounds which modulate atherosclerosis by impacting LDL-proteoglycan binding
  申请人：——

  公开号：US20010029027A1

  公开（公告）日：2001-10-11

  The present invention relates to the study and control of atherosclerosis through the modulation of LDL-proteoglycan binding at Site B (amino acids 3359-3369) of the apo-B100 protein in LDL. The invention encompasses methods of identifying compounds which modulate LDL-proteoglycan binding, methods of identifying compounds which modulate atherosclerotic lesion formation, and methods of modulating the formation of atherosclerotic lesions. The invention also encompasses mutant apo-B100 proteins and LDL which exhibit reduced proteoglycan binding while maintaining LDL-receptor binding, polynucleotides which encode these apo-B100 proteins, as well as cells and animals which express the mutant apo-B100 proteins.

  本发明涉及通过调节低密度脂蛋白中载脂蛋白-B100 蛋白的 B 位点（氨基酸 3359-3369）的低密度脂蛋白-蛋白多糖结合来研究和控制动脉粥样硬化。本发明包括鉴定调节低密度脂蛋白-蛋白聚糖结合的化合物的方法、鉴定调节动脉粥样硬化病变形成的化合物的方法以及调节动脉粥样硬化病变形成的方法。本发明还包括突变的载脂蛋白-B100 蛋白和低密度脂蛋白，它们在保持低密度脂蛋白受体结合力的同时，蛋白多糖结合力也有所降低；本发明还包括编码这些载脂蛋白-B100 蛋白的多核苷酸，以及表达突变载脂蛋白-B100 蛋白的细胞和动物。
• SELF-ASSEMBLING POLYNUCLEOTIDE DELIVERY SYSTEM
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：EP0636028A1

  公开（公告）日：1995-02-01